Technology

Artificial Intelligence Big Data Cloud Computing Cyber Security Data Management Electronics Enterprise & Network Technology Financial Technology Hardware Mobile & Wireless Nanotechnology Semiconductor Software Telecommunications
News Release Digital Asset Direct

Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)

Global Markets News

In a market where noise often overshadows substance, Nuvectis Pharma (NASDAQ:NVCT)* is delivering a signal that’s hard to ignore — sustained insider buying by one of the company’s most informed and sophisticated investors. On June 20, 2025, Charles Mosseri-Marlio, a well-known biotech investor and former pharmaceutical executive, filed a Form 4 disclosing the purchase of 33,442 additional shares of NVCT at $8.05 per share. The $270,000 transaction adds to his already significant position, which now totals just under 3 million shares through Emerald Hill Capital. This marks the third major insider buy by Mosseri-Marlio in 2025 alone — with previous purchases in February and May at lower price points. The pattern is clear: this is not opportunistic trading, it’s strategic accumulation. What makes this even more notable is Mosseri-Marlio’s background. He previously held a leadership role at Flamel Technologies (now Avadel Pharmaceuticals), where he helped secure development deals with top-tier partners like Pfizer and GlaxoSmithKline. He’s not only familiar with drug pipelines — he’s built them. Combined with a track record in institutional asset management, his buying carries more weight than your average insider move. He’s not chasing momentum — he’s betting on execution. And there’s plenty in the Nuvectis pipeline to justify that bet. The company is currently advancing two first-in-class oncology candidates — NXP800 and NXP900 — both of which are in clinical trials targeting cancers with high unmet need. NXP800 is in Phase 1b development for ARID1a-mutated, platinum-resistant ovarian cancer — a devastating subtype with few effective treatments. The drug has already earned Fast Track and Orphan Drug designations from the FDA, streamlining its development and signaling strong regulatory support. Data from this trial is expected later this year, and could be a key near-term catalyst. NXP900, meanwhile, is designed to address drug resistance in advanced cancers, including non-small cell lung cancer. By inhibiting SRC and YES1 kinases, NXP900 targets the very mechanisms that allow tumors to escape the effects of EGFR and ALK inhibitors — two of the most common first-line treatments in NSCLC. After completing its Phase 1a study, the company is now preparing to launch combination trials that could demonstrate its potential to restore drug sensitivity in resistant tumors. Despite these promising programs, Nuvectis remains deeply undervalued relative to peers. The company’s market cap sits around $150 million — a fraction of other precision oncology players at similar stages. Nuvalent (NASDAQ: NUVL), for example, trades north of $6 billion with programs focused on the same indication space. Summit Therapeutics (NASDAQ: SMMT), which also targets drug-resistant cancers, surged to nearly $15 billion in valuation earlier this year following a pivotal trial result. Nuvectis isn’t there yet — but if it delivers on either of its two clinical programs, it may not be far behind. Importantly, the company is financially stable. Nuvectis raised $15.5 million in early 2025, bringing its total cash reserves to nearly $30 million as of March. That provides runway into 2027, giving it ample time to reach key milestones without returning to the market for funding. It also means less dilution risk — a crucial factor for investors in early-stage biotech. This backdrop of strong insider ownership, solid financials, and high-impact drug development is what makes the Mosseri-Marlio buying spree so compelling. He’s not the only one with conviction either — CEO Ron Bentsur and other insiders continue to hold sizable stakes and have not sold a single share. Bentsur, notably, has a track record of taking biotech companies through FDA approval and delivering real value to shareholders. Year-to-date, NVCT is up significantly but it’s still relatively under the radar. That may not last long. With clinical data expected soon, strong internal alignment, and one of the most experienced insider buyers in the sector continuing to build his position, Nuvectis Pharma may be one of the few small-cap biotechs positioned for a breakout in the second half of 2025. - News Highlights from Nuvectis Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting - * Paid Advertisement Disclaimer & Disclosure: This content is not financial or investment advice, and the authors are not licensed brokers, dealers or advisors. This article was Published by the. Wall Street Wire™ platform and network, which is operated by Arx Advisory Ltd (the “Operators”). The Operators receive a monthly cash subscription fee from Nuvectis Pharma (NVCT) via bank transfer for services relating to promotional content and news distributions on various media and social channels. The Operators may received additional cash fees for monitoring, data or IR/advisory services on top of that. For specific details and full disclosures on the exact cash amounts paid for the Wall Street Wire subscription and the start date of such services, please refer to our full disclosure document: https://redditwire.com/terms Contact Details News Coverage media.globalmarkets@gmail.com

June 20, 2025 11:56 AM Eastern Daylight Time

With Fresh Funding and Strong Phase 3 Data, PolyPid Advances Towards FDA Approval

Global Markets News

PolyPid Ltd. (NASDAQ: PYPD) * announced Tuesday that it has secured $26.7 million through warrant exercises following its successful SHIELD II Phase 3 trial results. This funding milestone extends the company’s runway beyond the anticipated FDA approval of its breakthrough surgical infection prevention technology, D-PLEX₁₀₀. For savvy biotech investors seeking undervalued opportunities with near-term catalysts, PolyPid presents a compelling case study in market inefficiency and potential outsized returns. A David Taking On a $10 Billion Goliath Surgical site infections (SSIs) represent a massive burden on healthcare systems, costing hospitals tens of thousands of dollars per incident while significantly increasing patient mortality. The $10 billion SSI prevention market has long awaited innovation beyond traditional antibiotic approaches. Enter PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) platform, which delivers targeted antibiotics directly at surgical sites for a full 30 days—dramatically longer than conventional methods that typically provide only hours of protection. “D-PLEX₁₀₀ demonstrated a statistically significant reduction in surgical site infections and successfully met the study’s primary endpoint and all key secondary endpoints,” the company stated in its announcement of the Phase 3 SHIELD II trial results. Most impressively, in patients with large surgical incisions, earlier SHIELD I data showed a remarkable 54% reduction (p=0.0032) in the composite endpoint of infections, reinterventions, and mortality compared to standard of care alone. The more recent SHIELD II trial demonstrated an even more stunning 58% reduction in surgical site infections, dropping infection rates from 9.5% with standard care to just 3.8% when D-PLEX100 was added. Why This $36M Company Could Soon Command a Valuation in the Hundreds of Millions Despite delivering transformative clinical results, PolyPid currently trades around $3.53 per share (as of June 18, 2025), representing a market cap of approximately $36 million – a significant discount to comparable companies in the surgical and pain management sectors, many of which command valuations in the hundreds of millions to over $1 billion. This valuation disconnect creates a potential opportunity for investors ahead of multiple catalysts: 1. NDA Submission in Early 2026: The company expects to file its New Drug Application in early 2026, leveraging Fast Track and Breakthrough Therapy designations already granted by the FDA. 2. Medicare’s New Technology Add-On Payment Eligibility: D-PLEX₁₀₀ qualifies for this program, potentially providing up to 75% reimbursement during early commercialization years. 3. U.S. Partnership Discussions: Management noted during a recent call that there has been “a change in partnering interest following December’s interim analysis,” with large pharmaceutical and medical device companies representing logical partners. 4. Substantial Market Opportunity: With 12 million eligible surgeries annually in the U.S. alone and another 8 million in Europe, D-PLEX₁₀₀’s market potential is substantial. 5. European Partnership Already Secured: PolyPid has secured a European commercialization partnership with Advanz Pharma worth up to $115 million plus double-digit royalties. The newly secured $26.7 million adds to PolyPid’s existing capital resources. With this additional funding, the company has stated that its runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀. Beyond D-PLEX₁₀₀: Platform Technology Offers Additional Growth Potential While D-PLEX₁₀₀ drives immediate value creation, PolyPid’s broader PLEX platform provides significant growth opportunities beyond surgical infections. Their OncoPLEX program applies identical technology principles to deliver cancer therapeutics directly to tumor sites, potentially revolutionizing solid tumor treatment approaches. A recent collaboration with ImmunoGenesis validates the platform’s broader applications beyond surgical infections. According to recent analyst reports, Wall Street remains bullish on PolyPid. H.C. Wainwright recently raised their price target to $13 (from $11), while analysts from JMP Securities and Craig-Hallum have maintained Buy ratings. On June 5, 2025, Roth MKM initiated coverage with a Buy rating. The consensus among Wall Street professionals points to price targets ranging from $10-13, suggesting significant upside potential from current levels. The Bottom Line For investors seeking opportunities with clear catalysts, PolyPid represents a compelling combination of transformative clinical results, definitive regulatory pathway, and strong Wall Street support. With clinical risk substantially reduced following successful Phase 3 results and a regulatory submission timeline now established, the focus shifts to commercial execution and partnership value creation—potentially setting the stage for significant share price appreciation as these milestones materialize. The company’s notable discount to peers, extended cash runway, and multiple near-term value drivers make it an intriguing opportunity for biotech investors looking for undervalued assets with clear paths to value creation. Recent News Highlights from PolyPid PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints This article is syndicated from The Finance Herald. * Paid Advertisement Disclaimer & Disclosure: This article was Published by Wall Street Wire™. Wall Street Wire™ is owned and operated by Arx Advisory Ltd (the “Operator”). The Operator receives an ongoing monthly subscription fee of $5,000 cash via bank transfer (since May 1st, 2025 which is ongoing as of the date of publication) from PolyPid Ltd (PYPD) (IL0011326795) to produce and distribute this content and additional promotional content and news distributions on various media and social channels. The operator receives additional cash fees for non promotional data and consulting subscriptions from PolyPid. This content is not financial or investment advice, and the authors are not licensed brokers, dealers or advisors. Please refer to our full disclosure and disclaimer here: https://redditwire.com/terms. Contact Details Wall Street Wire media.globalmarkets@gmail.com

June 18, 2025 11:22 AM Eastern Daylight Time

Milemarker Elevates VP of Growth and Business Development Jessica Perez to Partner

Milemarker

Milemarker, the technology platform revolutionizing how RIAs, Broker-Dealers, Family Offices, and Private Equity firms scale with confidence, today announced the promotion of Jessica Perez to Partner. Since joining in June, Perez has been a driving force behind the company’s growth—sharpening the go-to-market strategy, strengthening national business development, and positioning Milemarker as the definitive operating system for advisory firms. A 20-year financial services veteran, Perez has expanded Milemarker’s reach through bold sales leadership and innovative top-of-funnel execution—from conferences and webinars to digital strategy and brand positioning. Her strategic lens and executional discipline have further cemented Milemarker’s role as the go-to solution for firms seeking clarity, control, and scale in their data and operations. “Jessica is a force in our industry,” said Jud Mackrill, Co-Founder & CEO of Milemarker. “She has the rare ability to lead as a strategist and deliver like an operator. Elevating her to Partner was not only well-earned—it positions us to scale even faster, with deeper conviction and impact.” Prior to Milemarker, Perez held senior leadership roles at Carson Group, where she helped raise over $6 billion in assets and onboarded more than 50 advisors and RIA offices. She also founded a successful consulting practice, advising firms on sales enablement, advisor recruiting, and leadership development. “Milemarker is reimagining what it means to operate a modern wealth management firm,” said Perez. “I’m honored to step into this new role alongside a team that’s committed to pushing the industry forward. What we’re building isn’t just tech—it’s the future infrastructure for wealth management.” About Milemarker Milemarker is a modern operating system for wealth management firms—built to unify data, streamline workflows, and drive better decisions across every corner of the business. Designed by operators for operators, Milemarker connects fragmented systems, automates key processes, and makes real-time insights accessible to both home offices and advisors. With seamless integration across the wealth management tech stack—portfolio systems, custodians, CRMs, planning tools, and more—Milemarker turns data chaos into clarity. Whether you’re centralizing investment operations, launching new accounts, or scaling a multi-office firm, Milemarker acts as your GPS, helping you grow with confidence and eliminate operational friction. Backed by an API-first, integration-friendly architecture and deployed in as little as one week, Milemarker enables firms to modernize infrastructure without compromising brand, security, or control. From trading to compliance to firm-wide analytics—Milemarker powers transformation at scale. Learn more at milemarker.co. Contact Details For Milemarker Lisa Aldape, Vocatus laldape@vocatusllc.com Company Website https://milemarker.co/

June 18, 2025 09:15 AM Eastern Daylight Time

Kevel Powers Kleinanzeigen's Next-Generation Retail Media Network

Kevel

Kevel, the industry leader in API-based ad serving technology, today announced that Kleinanzeigen, Germany's largest online classifieds platform, has chosen Kevel's Retail Media Cloud® to power its next-generation retail media network. This partnership marks a significant milestone in Kleinanzeigen's digital advertising strategy and underscores Kevel's expanding presence in the European market. By leveraging Kevel's cutting-edge technology, Kleinanzeigen aims to create a sophisticated, custom-built advertising platform that aligns with its commitment to connecting local buyers, marketplace sellers & brands. The new retail media network will enable Kleinanzeigen to offer its advertising partners more targeted and effective ways to enhance the user-experience and reach high-intent consumers with more than 700M monthly visits. Working closely with the Kevel team, Kleinanzeigen will utilize the Retail Media Cloud® to seamlessly integrate retail media offerings into its advertising strategy. This collaboration will focus on enhancing the user experience across both owned and off-site channels through personalization and innovative ad formats, leveraging Kleinanzeigen's unique first-party data. James Avery, Founder and CEO of Kevel, commented, "We are excited to welcome Kleinanzeigen to the Kevel family. Their decision to build their retail media network on our Retail Media Cloud® platform demonstrates the versatility and strength of our API-first approach. We look forward to helping Kleinanzeigen create a truly unique advertising experience that reflects their brand values and meets the evolving needs of both advertisers and users." Key benefits of the Kleinanzeigen-Kevel partnership include: Enhanced Scalability: Working with Kevel means Kleinanzeigen can now enhance their capabilities and build for scale to ensure they are efficiently and effectively working toward their goal of scaling its customer-base and ad inventory across their media network. Diverse Ad Formats: Kevel's platform supports a wide range of ad units, allowing Kleinanzeigen to implement native ads, sponsored listings, and other custom formats seamlessly. Rapid Deployment: With Kevel's technology, Kleinanzeigen can launch custom retail media campaigns in as little as 14 days, ensuring agility and responsiveness to market demands. Data Compliance and Security: Kevel's industry-leading data compliance features allow Kleinanzeigen to confidently use its user data while maintaining strict privacy standards. Improved Advertiser ROI: More precise targeting and diverse ad formats are expected to significantly enhance returns for Kleinanzeigen's advertising partners. Fabian Schmitt-Pfeifer, Head of Product Retail Media at Kleinanzeigen, said, "At Kleinanzeigen, we're constantly seeking innovative ways to improve our users' experience and provide value to our advertising partners. Kevel gives us the tools and flexibility we need to build a retail media network that's uniquely tailored to our platform. We're excited about the possibilities this opens up for our business, our users, and our advertising partners." The implementation of Kevel's Retail Media Cloud® began earlier this year with the first ad placements going live in April and is expected to be completed in phases over the coming months. About Kevel Kevel powers innovative, flexible ad tech infrastructure APIs that fuel its ad serving solutions. It’s unique offering empowers multi-brand retailers to launch differentiated retail media networks that improve the shopper experience while maintaining total control of their first-party data. Kevel believes that every digital retailer should have the capability to scale their own distinct ad platform, just like big tech players like Amazon. Customers like Edmunds, Klarna, Delivery Hero, Leroy Merlin, Slickdeals, and other leading retailers and marketplaces all launched their own retail media network with Kevel. The company has garnered numerous accolades, most recently earning recognition as one of the leading 100 innovative tech start-ups driving the future of brand-to-consumer in 2023 and awarded the MarTech Breakthrough Award for best overall ad tech company in 2022. Learn more at www.kevel.com About Kleinanzeigen Kleinanzeigen is the leading online classifieds platform in Germany. On average, more than 55 million ads are posted in a wide range of categories – from children's needs to electronics and real estate. Most of the items listed are second-hand. In this way, users make an active contribution to greater sustainability. Kleinanzeigen also offers companies the opportunity to present their services online in a simple way. Kleinanzeigen was launched in September 2009 as eBay Kleinanzeigen. In May 2023, the company was renamed Kleinanzeigen. Contact Details Kevel Jennifer Choo Director of Marketing +1 973-343-8819 pr@kevel.com

June 18, 2025 09:01 AM Eastern Daylight Time

Kevel Powers Kleinanzeigen's Next-Generation Retail Media Network

Kevel

Kevel, the industry leader in API-based ad serving technology, today announced that Kleinanzeigen, Germany's largest online classifieds platform, has chosen Kevel's Retail Media Cloud® to power its next-generation retail media network. This partnership marks a significant milestone in Kleinanzeigen's digital advertising strategy and underscores Kevel's expanding presence in the European market. By leveraging Kevel's cutting-edge technology, Kleinanzeigen aims to create a sophisticated, custom-built advertising platform that aligns with its commitment to connecting local buyers, marketplace sellers & brands. The new retail media network will enable Kleinanzeigen to offer its advertising partners more targeted and effective ways to enhance the user-experience and reach high-intent consumers with more than 700M monthly visits. Working closely with the Kevel team, Kleinanzeigen will utilize the Retail Media Cloud® to seamlessly integrate retail media offerings into its advertising strategy. This collaboration will focus on enhancing the user experience across both owned and off-site channels through personalization and innovative ad formats, leveraging Kleinanzeigen's unique first-party data. James Avery, Founder and CEO of Kevel, commented, "We are excited to welcome Kleinanzeigen to the Kevel family. Their decision to build their retail media network on our Retail Media Cloud® platform demonstrates the versatility and strength of our API-first approach. We look forward to helping Kleinanzeigen create a truly unique advertising experience that reflects their brand values and meets the evolving needs of both advertisers and users." Key benefits of the Kleinanzeigen-Kevel partnership include: Enhanced Scalability: Working with Kevel means Kleinanzeigen can now enhance their capabilities and build for scale to ensure they are efficiently and effectively working toward their goal of scaling its customer-base and ad inventory across their media network. Diverse Ad Formats: Kevel's platform supports a wide range of ad units, allowing Kleinanzeigen to implement native ads, sponsored listings, and other custom formats seamlessly. Rapid Deployment: With Kevel's technology, Kleinanzeigen can launch custom retail media campaigns in as little as 14 days, ensuring agility and responsiveness to market demands. Data Compliance and Security: Kevel's industry-leading data compliance features allow Kleinanzeigen to confidently use its user data while maintaining strict privacy standards. Improved Advertiser ROI: More precise targeting and diverse ad formats are expected to significantly enhance returns for Kleinanzeigen's advertising partners. Fabian Schmitt-Pfeifer, Head of Product Retail Media at Kleinanzeigen, said, "At Kleinanzeigen, we're constantly seeking innovative ways to improve our users' experience and provide value to our advertising partners. Kevel gives us the tools and flexibility we need to build a retail media network that's uniquely tailored to our platform. We're excited about the possibilities this opens up for our business, our users, and our advertising partners." The implementation of Kevel's Retail Media Cloud® began earlier this year with the first ad placements going live in April and is expected to be completed in phases over the coming months. About Kevel Kevel is revolutionizing retail media with its AI-powered, API-first Retail Media Cloud®, empowering retailers, marketplaces, and eCommerce platforms to build, level up, and scale custom ad networks while maintaining full control of their first-party data. By offering unparalleled flexibility in ad serving, audience segmentation, and self-serve capabilities, Kevel enables businesses to launch impactful retail media programs in weeks, not years. Kevel's mission is rooted in the belief that every digital retailer should have the tools to create their own tailored ad platform, comparable to industry leaders like Amazon. Harnessing the power of AI for data-driven decision-making, Kevel has helped leading brands such as Chewy, The Home Depot, Dollar General, John Lewis, Sonae, Lyft, El Corte Ingles, Slickdeals, and others launch impactful retail media networks—fostering innovation and unlocking new revenue opportunities. With Kevel, businesses can differentiate their ad programs, maximize their share of media dollars, and take control of their retail media destiny. Discover the power of customization and performance at www.kevel.com. About Kleinanzeigen Kleinanzeigen is the leading online classifieds platform in Germany. On average, more than 55 million ads are posted in a wide range of categories – from children's needs to electronics and real estate. Most of the items listed are second-hand. In this way, users make an active contribution to greater sustainability. Kleinanzeigen also offers companies the opportunity to present their services online in a simple way. Kleinanzeigen was launched in September 2009 as eBay Kleinanzeigen. In May 2023, the company was renamed Kleinanzeigen. Contact Details Kevel Jennifer Choo Director of Marketing +1 973-343-8819 jchoo@kevel.com

June 17, 2025 09:00 AM Eastern Daylight Time

BiomX Stock Could Soar 3000% As This $10M Biotech Cracks The 'Superbug' Code, Wall Street Says

Global Markets News

BiomX Inc. (NYSE: PHGE)* has achieved what Big Pharma couldn't accomplish in over 20 years — successful clinical trials using viruses to treat life-threatening infections that no longer respond to antibiotics. The $10 million biotech has reported positive Phase 2 results in diabetic foot bone infections, a condition so challenging that no new drugs have been approved for it in two decades. Meanwhile, their cystic fibrosis program showed 14% of patients completely cleared chronic lung infections after just 10 days of treatment. Approximately 160,000 lower limb amputations occur annually in diabetic patients in the U.S., with 85% caused by diabetic foot infections or diabetic foot osteomyelitis — creating an $8 billion annual healthcare burden according to company data. Current treatments rely on antibiotics that increasingly fail due to resistance, often leaving amputation as the only option. Clinical Breakthroughs Across Two Major Programs BiomX's March 2025 Phase 2 results in diabetic foot osteomyelitis from 41 patients delivered notable outcomes. The company achieved statistically significant percent area reduction of ulcer size, with p-values of 0.046 at week 12 and 0.052 at week 13. The treatment showed separation from placebo starting at week 7, with differences greater than 40% by week 10. BiomX also demonstrated statistically significant improvements in ulcer depth and reducing ulcer area expansion, while BX211 was safe and well-tolerated throughout the study. The company's cystic fibrosis program has been equally impressive. In their Phase 1b/2a study, 14.3% of patients converted to sputum culture negative for P. aeruginosa after 10 days of treatment, compared to 0% in the placebo group. One patient had been infected for 35 years before achieving complete clearance. The FDA has granted this program both Fast Track designation and Orphan Drug Designation, potentially accelerating the approval pathway. BiomX's approach uses bacteriophages — viruses that naturally target and kill specific bacteria — instead of traditional antibiotics that bacteria can develop resistance against. The company has overseen more than 50 compassionate use cases with no significant side effects to date. Military Validation and Wall Street's Bullish Take The U.S. Defense Health Agency has provided $40 million in non-dilutive funding to BiomX's diabetic foot program, representing significant validation of the technology. "They're seeing soldiers coming out of the Ukraine war with extremely antibiotic-resistant infections," CEO Jonathan Solomon said during the company's May 2025 earnings call. Despite the clinical progress and military backing, BiomX trades at approximately $10 million market cap — a disconnect0 that has caught Wall Street's attention. H.C. Wainwright maintains a Buy rating with a $15 price target, representing potential upside of over 3000% from recent levels around $0.4 Laidlaw & Company rates the stock Buy with a $16 price target, suggesting almost 4000% upside potential. Laidlaw analyst Yale Jen called the recent data "an absolutely positive surprise" and characterized BX211 as "a high value and clinically de-risked asset." The analysts' optimism stems from the clinical validation across both programs, massive addressable markets, and limited competition in the phage therapy space. Major Catalysts on the Horizon BiomX estimates addressable markets exceeding $2.5 billion globally for their diabetic foot program and $1.6 billion for cystic fibrosis based on patient populations and potential pricing benchmarks. The company expects to have sufficient funding through Q1 2026, aligning with anticipated BX004 Phase 2b results in cystic fibrosis. Key upcoming catalysts include the Phase 2b readout for their cystic fibrosis program expected in Q1 2026, ongoing Phase 2/3 trial discussions with the FDA for their diabetic foot program, and potential regulatory meetings in the second half of 2025. The company is also exploring partnership opportunities as the phage therapy space attracts increasing attention from large pharmaceutical companies. With validated clinical data, military funding, and Wall Street price targets suggesting potential returns exceeding 3000%, BiomX could offer investors exposure to phage therapy as a potential new approach to treating antibiotic-resistant infections. As the global antibiotic resistance crisis intensifies, the company's nature-based approach to killing bacteria positions it at an interesting inflection point in infectious disease treatment. BiomX shares were trading at ~$0.4 at last check Recent News Highlights from BiomX BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) * Legal Disclaimer & Disclosure: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by Wall Street Wire™. The operators of Wall Street Wire, arx advisory, are not registered brokers, dealers, or investment advisers. This report contains and is a form of paid promotional content or advertisement for BiomX Inc and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by BiomX Inc prior to publication. The operators of wall street wire have received or are expected to receive a monthly recurring fee of five thousand united states dollars via wire transfer from BiomX as part of an ongoing agreement starting June 1st, 2025 in return for social media distribution and promotional coverage services, and receive additional compensation for non promotional unrelated data and advisory services on top of that. They do not hold any shares in BiomX. Please review the full disclaimers and compensation disclosures here for further details: redditwire.com/terms. We are not responsible for the price targets mentioned in this article nor do we endorse them, they are quoted based on publicly available news reports believed to be reliable and additional or price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details News Coverage ronald@futuremarketsresearch.com

June 16, 2025 07:04 PM Eastern Daylight Time

$USD1 Stablecoin Begins Minting on TRON

TRON DAO

Geneva, Switzerland, June 12, 2025 – TRON DAO, the community-governed DAO dedicated to accelerating the decentralization of the internet through blockchain technology and decentralized applications (dApps), has announced the first minting of the USD1 stablecoin on the TRON blockchain. Released by World Liberty Financial., the developer of a pioneering DeFi protocol and governance platform inspired by President Donald J. Trump, USD1 is 100% backed by short-term US government treasuries, US dollar deposits, and other cash equivalents. The minting of WLFI’s stablecoin on TRON confirms an announcement made last month at Token2049 in Dubai by Eric Trump, executive vice president of the Trump Organization and co-founder of WLFI. Trump announced in May that USD1 was the stablecoin selected to settle MGX’s $2 billion investment in Binance, quickly followed by a supporting statement that USD1 will be fully integrated into the TRON ecosystem. The minting kicked off in the early morning hours of June 11, documented by an X post from TRON founder Justin Sun, who described this milestone as a “giant leap for stablecoins.” “From launching new ideas to challenging how we think about money and freedom, it’s clear that we are making progress in moving the crypto industry forward,” said Sun. “It has been great to be part of this process with WLFI and to see the Trump administration taking steps to create a clearer and more supportive environment for innovation.” The integration of USD1 as an independent and secure stablecoin strengthens the TRON ecosystem while advancing their ongoing mission to promote economic growth. By offering the transparency and security that institutions demand, USD1 positions TRON for even broader institutional adoption. WLFI's strategic decision to mint USD1 on TRON signals a growing trust in the network's robust infrastructure and demonstrates increasing institutional confidence in TRON’s ability to deliver secure, scalable blockchain solutions for global markets. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON blockchain has experienced significant growth since its MainNet launch in May 2018. TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin, exceeding $78 billion. As of May 2025, the TRON blockchain has recorded over 312 million in total user accounts, more than 10 billion in total transactions, and over $22 billion in total value locked (TVL), based on TRONSCAN. TRONNetwork | TRONDAO | X | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Yeweon Park press@tron.network Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

June 12, 2025 08:24 PM Eastern Daylight Time

Image

farm-ng Latest User-Friendly Software Empowers Small and Mid-Sized Farms with Smarter Automation

farm-ng

farm-ng, a leader in accessible agricultural robotics, announced significant updates to its on-robot software stack, reinforcing the company’s dedication to providing affordable, practical and easy-to-use solutions for small and medium-sized farms. These enhancements focus on a streamlined, grower-centric user interface (UI), automated implement control within farming zones, improved accuracy in hands-free navigation mode, and a new Job Manager to simplify operations and increase efficiency in the field. "Our goal has always been to empower farmers with equipment that is both powerful and affordable," said Brendan Dowdle, CEO of farm-ng. "These latest enhancements to the Amiga robotic platform are a direct response to feedback from our users, aiming to make advanced agricultural technology accessible for farms of all sizes." The updated UI gives growers an intuitive dashboard to monitor robot health, switch between apps, and manage implements with ease, such as toggling sprayers on/off or setting tools to operate for specific durations. This design ensures that even those with minimal technical experience can effectively utilize the Amiga robot. The new Job Manager lets users plan, save, and repeat complete tasks within defined paths and zones—enabling hands-free operations like seeding, weeding, or spraying with precision tool control. This streamlines repetitive work, saves time, and minimizes human error. These updates are available over-the-air (OTA), ensuring that existing Amiga users can seamlessly upgrade their systems without the need for additional hardware or complex installations. For more information about the Amiga robot and the latest updates, please visit www.farm-ng.com. About farm-ng Based in Watsonville, California, farm-ng is an agricultural robotics company supporting productivity and innovation in the field. Its flagship product – the Amiga – is a modular, electric, open-architecture robot designed to serve small- and mid-sized farms, research institutions, and developers. From crop care to data collection, farm-ng empowers the ag community to solve today’s challenges and build tomorrow’s solutions. Contact Details AgTech PR Sara Winters sara@agtechpr.com

June 11, 2025 09:15 AM Pacific Daylight Time

Image

Sheon Karol Joins West Lane Partners as Senior Advisor

West Lane Partners

West Lane Partners, a private equity firm focused on special situations in middle market companies spanning healthcare, tech, financial services and industrials, is pleased to announce that Sheon Karol, a nationally recognized investment banker and restructuring advisor, has joined the firm as a Senior Advisor. Mr. Karol brings over three decades of experience in investment banking, restructuring, and senior corporate leadership, with deep expertise in complex M&A, capital raises, and operational turnarounds. Skilled in de-risking situations, he brings a flexible yet disciplined approach that favors iterative decision-making over rigid or binary choices. His ability to surface a range of strategic options, often under pressure, has made him a trusted advisor to owners navigating both opportunity and uncertainty. His contributions to the field have earned national recognition, including the “Boutique Investment Banker of the Year” award from the Atlas Awards. “Sheon and I have been in the trenches together on complex deals. He’s masterful at aligning stakeholders, cutting through noise, and adapting in real time to keep transactions on course. Where others see roadblocks, he sees possibility—and responds with clarity and flexibility,” said Deryck Palmer, Founder and Managing Partner at West Lane Partners. “His dynamic approach, experience, and deep market insight into the industries on which we’re focused, and an instinct for what owners value most, makes him an exceptional addition to our firm.” “I think of the middle market as the river less fished” said Mr. Karol. “Middle market companies are often overlooked, undercapitalized, and underserved by institutional talent. At West Lane Partners, our focus on investments between $25 million and $75 million is about more than deal size—it’s about bringing high-caliber insight to businesses at pivotal moments and tailoring strategic options to match the evolving goals of owners and the realities of the market. The result is not just getting deals done, but generating long-term value others might miss.” Mr. Palmer added, “I’ve always been impressed by Sheon’s expertise, creativity, positivity and determination to get the best for his clients. These qualities enable him to inexorably bring difficult situations to their best possible conclusion and there are few who bring such capabilities to the middle market.” About Sheon Karol Mr. Karol has advised on high-stakes transactions across a myriad of industries in the middle market, including manufacturing, biotech, pharma, for-profit education, medical research, agriculture, consumer goods, food & grocery, sports, and technology. Mr. Karol has successfully executed a wide range of strategic transactions, including M&A advisory, capital raises, and restructurings, for both healthy and distressed businesses and their stakeholders. He has also served in executive capacities, including as Chief Restructuring Officer of a $1 billion company, for which he renegotiated the company's debt and avoided a bankruptcy filing. Many of Mr. Karol’s transactions, including Violin Memory and Peekay Boutiques, have won awards. He served as SVP of Winn-Dixie and managed the company's sale of assets in excess of $200 million and the disposition of 326 stores (in a 90-day period); guided the auction and sale of Farmland’s nitrogen fertilizer business that exceeded the “stalking horse” bid by $25 million; advised the CRO in the sale of the Texas Rangers baseball team; and advised foreign buyers in their U.S. expansion. Trustee positions include the Violin Memory and Lily Robotics Trusts. A middle market M&A thought leader, he writes and lectures widely, including on entrepreneurship, auction theory, sale processes, the middle market and foreign buyers. He holds FINRA SIE, Series 63 and Series 79 certifications. Mr. Karol received a J.D. from Yale Law School and a B.A. from Yeshiva College. About West Lane Partners West Lane Partners is a private equity firm whose senior leadership has over 150 years of collective restructuring and private equity experience working with underperforming, stressed and distressed companies across a range of industries in both large cap and middle market companies. In addition to providing capital, the firm combines decades of restructuring, private equity, legal and financial expertise to collaborate with management in developing and executing bespoke solutions that deliver mutually beneficial outcomes. Contact Details Curtis Johnson, Investor Relations +1 973-404-0999 cjohnson@westlanepartners.com Meir Kahtan Public Relations, LLC Meir Kahtan +1 917-864-0800 mkahtan@rcn.com Company Website https://www.westlanepartners.com

June 11, 2025 10:00 AM Eastern Daylight Time

1 2 3 4 5 ... 644